Apnimed Rises On Its Public Debut As More Drug Developers Prepare IPO Launches Scrip Pharma Intelligence 01:44
With sleep apnea drug under review, Apnimed prices $192M IPO BioWorld 20:30 Fri, 31 Jul Article paywall
Apnimed Announces Pricing of Upsized Initial Public Offering PR Newswire (Press Release) 03:13 Fri, 31 Jul
Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development Pharmaceutical Technology 12:04 Tue, 28 Jul
Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (Osa) PR Newswire (Press Release) 13:03 Tue, 14 Jul
